TR201821161T4 - Biyofilm Organizmalarının İnhibisyonu - Google Patents

Biyofilm Organizmalarının İnhibisyonu Download PDF

Info

Publication number
TR201821161T4
TR201821161T4 TR2018/21161T TR201821161T TR201821161T4 TR 201821161 T4 TR201821161 T4 TR 201821161T4 TR 2018/21161 T TR2018/21161 T TR 2018/21161T TR 201821161 T TR201821161 T TR 201821161T TR 201821161 T4 TR201821161 T4 TR 201821161T4
Authority
TR
Turkey
Prior art keywords
inhibition
biofilm organisms
product
antibiofilm
biofilm
Prior art date
Application number
TR2018/21161T
Other languages
English (en)
Turkish (tr)
Inventor
O'neil Deborah
Mercer Derry
Charrier Cedric
Original Assignee
Novabiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novabiotics Ltd filed Critical Novabiotics Ltd
Publication of TR201821161T4 publication Critical patent/TR201821161T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N33/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic nitrogen compounds
    • A01N33/02—Amines; Quaternary ammonium compounds
    • A01N33/08—Amines; Quaternary ammonium compounds containing oxygen or sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/254—Enzymes, proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/424—Anti-adhesion agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Plant Pathology (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2018/21161T 2009-03-31 2010-03-31 Biyofilm Organizmalarının İnhibisyonu TR201821161T4 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16539609P 2009-03-31 2009-03-31
GBGB0905451.1A GB0905451D0 (en) 2009-03-31 2009-03-31 Biofilms

Publications (1)

Publication Number Publication Date
TR201821161T4 true TR201821161T4 (tr) 2019-01-21

Family

ID=40671951

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/21161T TR201821161T4 (tr) 2009-03-31 2010-03-31 Biyofilm Organizmalarının İnhibisyonu

Country Status (21)

Country Link
US (3) US9339525B2 (enExample)
EP (1) EP2413949B1 (enExample)
JP (1) JP5727994B2 (enExample)
KR (1) KR101852784B1 (enExample)
CN (2) CN104257645A (enExample)
AU (2) AU2010231136B2 (enExample)
BR (1) BRPI1012219C1 (enExample)
CA (1) CA2755878C (enExample)
CY (1) CY1121175T1 (enExample)
GB (1) GB0905451D0 (enExample)
IL (1) IL215369B2 (enExample)
MX (1) MX358018B (enExample)
NZ (1) NZ595037A (enExample)
PL (1) PL2413949T3 (enExample)
RU (1) RU2548786C2 (enExample)
SG (2) SG10201400926VA (enExample)
SI (1) SI2413949T1 (enExample)
TR (1) TR201821161T4 (enExample)
UA (1) UA106743C2 (enExample)
WO (1) WO2010112848A2 (enExample)
ZA (1) ZA201107140B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
TWI403330B (zh) * 2010-03-29 2013-08-01 Rise technology co ltd 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
GB201016733D0 (en) * 2010-10-05 2010-11-17 Novabiotics Ltd Compounds and their use
EA037276B1 (ru) 2010-04-27 2021-03-03 Лисандо Аг Способы устранения или уменьшения бактериальной биопленки
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
CN103687610A (zh) 2011-05-12 2014-03-26 史密夫和内修整形外科股份公司 含有蜂蜜曲霉蛋白酶的伤口清创组合物和使用其治疗伤口的方法
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
WO2013076666A1 (en) * 2011-11-23 2013-05-30 Newsouth Innovations Pty Limited Antimicrobial peptides and uses thereof
WO2013142374A1 (en) 2012-03-23 2013-09-26 Amirobe, Inc. Compositions and uses of antimicrobial materials with tissue-compatible properties
AU2013259360B2 (en) * 2012-05-11 2017-07-13 Smith & Nephew, Inc. Use of Seaprose to remove bacterial biofilm
WO2014016979A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物活性調節剤及び微生物の活性を調節する方法
WO2015038339A1 (en) * 2013-08-27 2015-03-19 The University Of British Columbia Small cationic anti-biofilm and idr peptides
GB201405891D0 (en) * 2014-04-02 2014-05-14 Novabiotics Ltd Modified antimicrobial peptides
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds
GB201416727D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
GB201510077D0 (en) * 2015-06-10 2015-07-22 Novabiotics Ltd Use
WO2017134661A1 (en) * 2016-02-04 2017-08-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for disrupting biofilms
JP2019510076A (ja) * 2016-02-19 2019-04-11 フォルシュングスツェントルム ボルシュテル ライプニッツツェントルム フュール メディツィン ウント ビオヴィッセンシャフテン 細菌感染症を治療するための手段と方法
US20190071706A1 (en) 2016-04-04 2019-03-07 University Of Virginia Patent Foundation Compositions and methods for preventing and treating disease
EP3241570A1 (en) * 2016-05-02 2017-11-08 Institut National De La Sante Et De La Recherche Medicale (Inserm) Polypeptide and hyaluronic acid coatings
US11246819B2 (en) * 2016-05-12 2022-02-15 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting biofilm deposition and production
WO2017212239A1 (en) * 2016-06-07 2017-12-14 Novabiotics Limited Treatment of drug-resistant microbial infections
AU2017304271B2 (en) 2016-07-27 2024-07-18 Smith & Nephew, Inc. Use of thermolysin to reduce or eliminate bacterial biofilms from surfaces
AU2017376391B2 (en) 2016-12-15 2023-06-01 Zambon S.P.A. N-acetylcysteine for use as antibacterial agent
AU2017381394A1 (en) * 2016-12-22 2019-07-25 The University Of Sydney Biofilm disrupting composition
CN110573192A (zh) * 2017-01-05 2019-12-13 科医公司 针对成熟生物膜有效的包括抗微生物水凝胶的抗微生物组合物
WO2018140707A1 (en) 2017-01-30 2018-08-02 Smith & Nephew, Inc. Synergistic combination of thermolysin and an antibacterial agent to reduce eliminate bacterial biofilms from surfaces
KR20200018400A (ko) 2017-04-06 2020-02-19 아미크로베, 인코포레이티드. 개선된 성능 및 안전성을 가진 국소적으로 적용된 항균제의 조성물 및 용도
RU2664708C1 (ru) * 2017-06-08 2018-08-21 Сергей Иванович Черныш Способ разрушения и предотвращения образования бактериальных биопленок комплексом антимикробных пептидов насекомых
CN108048359B (zh) * 2017-12-27 2020-12-01 广州立白企业集团有限公司 一种牙菌斑生物膜模型的培养方法和优化的生物膜活菌计数法及应用
EP3765057A4 (en) * 2018-03-13 2022-01-05 Peptilogics, Inc. TREATMENT OF IMPLANTS WITH SPECIFICALLY MODIFIED ANTIMICROBIAL AMPHIPHILE PEPTIDES
CN108753632A (zh) * 2018-05-25 2018-11-06 安徽中医药大学 一种溶解白念珠菌生物被膜胞外基质的方法
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
ES3024695T3 (en) * 2018-10-17 2025-06-05 Novabiotics Ltd Cysteamine for use in the treatment of lung diseases
CN110402928A (zh) * 2019-08-08 2019-11-05 杭州博菲医疗器械有限公司 一种抑菌功能液及应用该抑菌功能液的导管组件
CN110583697B (zh) * 2019-09-20 2021-04-06 浙江工商大学 去除铜绿假单胞菌生物膜用的高效化学生物制剂及其应用
CN111675751B (zh) * 2020-04-08 2022-06-14 天津医科大学口腔医院 一种抗菌肽及其应用
GB202010268D0 (en) * 2020-07-03 2020-08-19 Novabiotics Ltd Nail formulations and treatment regimes
US12371463B2 (en) 2021-04-20 2025-07-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods and compositions for treatment of antibiotic-resistant bacterial infections

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1055560B (it) * 1974-05-02 1982-01-11 Istituto Chemioterapico Derivati pirimidinici e relative composizioni per il trattamento di infezioni virali
AU2042200A (en) * 1998-12-07 2000-06-26 Baylor College Of Medicine Preventing and removing biofilm from the surface of medical devices
ITMI20021881A1 (it) * 2002-09-04 2004-03-05 Zambon Spa Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
CN103360486A (zh) * 2004-08-18 2013-10-23 诺瓦生命科学有限公司 包含含有精氨酸和/或赖氨酸的基序的抗微生物肽
US20070093894A1 (en) * 2005-10-25 2007-04-26 Baylor College Of Medicine Incorporation of antimicrobial combinations onto devices to reduce infection
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
CN101340902B (zh) * 2005-11-28 2011-01-26 奥加生物药业（香港）有限公司 用半胱胺化合物处理病毒感染的材料和方法
GB0702021D0 (en) * 2007-02-02 2007-03-14 Novabiotics Ltd Peptides and their use
US20100151042A1 (en) * 2007-05-25 2010-06-17 Hao Yi Liang Materials and Methods for Treating Influenza Infections
CN102006785A (zh) * 2008-02-17 2011-04-06 华扩达动物科学(I.P.3)有限公司 改善虾健康的材料和方法
GB0905451D0 (en) * 2009-03-31 2009-05-13 Novabiotics Ltd Biofilms
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
US20160106689A1 (en) * 2014-09-22 2016-04-21 Novabiotics Limited Use
US20160102052A1 (en) * 2014-09-22 2016-04-14 Novabiotics Limited Use of Cysteamine in Treating Infections caused by Yeasts/Moulds

Also Published As

Publication number Publication date
PL2413949T3 (pl) 2019-04-30
EP2413949A2 (en) 2012-02-08
CY1121175T1 (el) 2020-05-29
WO2010112848A2 (en) 2010-10-07
CA2755878C (en) 2018-04-24
AU2016210742B2 (en) 2017-08-10
RU2548786C2 (ru) 2015-04-20
CA2755878A1 (en) 2010-10-07
CN104257645A (zh) 2015-01-07
AU2010231136B2 (en) 2016-08-04
IL215369A (en) 2013-02-03
BRPI1012219A2 (pt) 2016-03-29
GB0905451D0 (en) 2009-05-13
SI2413949T1 (sl) 2019-02-28
WO2010112848A3 (en) 2011-01-27
US20160206575A1 (en) 2016-07-21
US9339525B2 (en) 2016-05-17
IL215369B2 (en) 2023-02-01
NZ595037A (en) 2013-07-26
BRPI1012219B8 (pt) 2020-05-12
KR20120003893A (ko) 2012-01-11
AU2010231136A1 (en) 2011-09-29
US20120189682A1 (en) 2012-07-26
KR101852784B1 (ko) 2018-04-30
AU2016210742A1 (en) 2016-08-25
ZA201107140B (en) 2012-06-27
UA106743C2 (uk) 2014-10-10
JP2012522037A (ja) 2012-09-20
CN102387794A (zh) 2012-03-21
SG10201400926VA (en) 2014-10-30
MX358018B (es) 2018-08-02
IL215369B (en) 2022-10-01
BRPI1012219C1 (pt) 2021-05-25
EP2413949B1 (en) 2018-10-10
JP5727994B2 (ja) 2015-06-03
MX2011010258A (es) 2011-10-19
CN102387794B (zh) 2015-11-25
SG174278A1 (en) 2011-10-28
US20190175528A1 (en) 2019-06-13

Similar Documents

Publication Publication Date Title
TR201821161T4 (tr) Biyofilm Organizmalarının İnhibisyonu
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
DE602008000754D1 (de) Tropanverbindungen
UA106748C2 (uk) Похідні проліну як інгібітори катепсину
MY160771A (en) Heterocyclic compound and use thereof
BRPI0717266A2 (pt) Derivados de oxindol
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
WO2011045703A3 (en) C-linked hydroxamic acid derivatives useful as antibacterial agents
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
MX2013011432A (es) Derivados de imidazol, pirazol, y triazol utiles como agentes antibacterianos.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
NZ596628A (en) Ketolide compounds having antimicrobial activity
TR201908180T4 (tr) N1-asil- 5-floropirimidinon deriveleri.
EA201001495A1 (ru) Карналлит-подобные пищевые соли и продукты из них
NI201000047A (es) Uso de 3, 11b-cis-dihidrotetrabenzina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria.
BRPI0807066A8 (pt) Combinações sinergísticas de compostos ativos fungicidas
EP2303271A4 (en) TREATMENT OF ANTIBIOTICS-RESISTANT BACTERIAL INFECTION
MX2016010385A (es) Agentes antibacterianos.
GT201000298A (es) 2,6-diamino-pirimidin-z-il-carboxamidas como inhibidores de syk o jak quinasas
MY205944A (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
RU2009144827A (ru) 4-{3,5-диоксо-4-азатетрацикло[5.3.2.0 2,6. 0 8,10.]додец-11-ен-4-ил}-4-азатетрацикло[5.3.2.0 2,6. 0 8,10.]додец-11-ен-3,5-дион, обладающий противовирусной активностью в отношении ортопоксвирусов
WO2008065409A3 (en) Combination for use in the treatment of cancer, comprising tamoxifen or an aromatase inhibitor
EP2312952A4 (en) ANTIMICROBIAL COMPOSITION
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.